Daa Pangenotypic Mavyret denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for daa pangenotypic mavyret are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applied Step Therapy to Mavyret

Step therapy (also called "fail-first") denials for Mavyret (glecaprevir/pibrentasvir) require the patient to try and document failure of — or intolerance to — one or more alternative hepatitis C treatments before UnitedHealthcare will approve Mavyret. For pangenotypic DAAs, step-therapy requirements are medically controversial because the clinical and guideline communities have largely moved toward genotype-informed or pangenotypic first-line regimens. If your prescriber chose Mavyret as a first-line agent based on clinical factors, documenting that rationale explicitly is essential.

## Why This Denial Is Appealable

Step-therapy denials are routinely overturned when the prescriber provides a clinical rationale explaining why the required alternative is contraindicated, clinically inferior, or otherwise inappropriate for this patient. Many states have enacted step-therapy override laws that require insurers to grant exceptions when a required alternative is not in the patient's best clinical interest — check your state's current step-therapy legislation. Even in states without explicit laws, ERISA §503's full-and-fair review standard requires UHC to weigh prescriber-supplied clinical evidence.

## Federal and State Appeal Framework

• Step-therapy exception request: File this first, simultaneously with the internal appeal, to preserve all pathways.
• Internal appeal (ERISA §503 / ACA §2719): Submit within the deadline on the denial letter. UHC must conduct a full-and-fair review that considers clinical evidence submitted by your prescriber.
• State step-therapy override law: If your state has enacted a step-therapy reform law, cite it in the appeal and specify the applicable exception ground (e.g., alternative is contraindicated, patient previously failed the alternative, clinical exception applies).
• External review: Available after a final internal denial, within approximately four months. Expedited review available when medically urgent.

## Concrete Appeal Steps

1. Obtain UHC's step-therapy policy: identify exactly which drug(s) must be tried first and what constitutes adequate trial/failure. 2. Review the patient's chart for any prior HCV treatment, prior DAA exposure, drug interactions, comorbidities, or other factors that support skipping the required step. 3. Have the prescriber write a step-therapy exception letter that addresses each required alternative and explains the clinical basis for the exception. 4. Submit the exception request and internal appeal together with supporting chart documentation. 5. If applicable, cite your state's step-therapy override statute in the cover letter. 6. If denied internally, file external review immediately.

## Documentation to Gather

• Diagnosis: HCV genotype, viral load, treatment history
• Prior treatment records: any prior DAA or interferon-based treatment with dates, regimens, and outcomes
• Comorbidity documentation: any conditions relevant to why the required step drug is not appropriate
• Prescriber exception letter: addresses each required step drug and the clinical basis for bypassing it
• Applicable state step-therapy statute citation (if your state has one)

## Criteria-Mapping Structure

List each step UHC requires in column one. In column two, state the outcome: either (a) the patient completed that step and failed — cite the chart date and result — or (b) the prescriber certifies the step is not clinically appropriate and gives the specific clinical reason. A completed table directly answers every step UHC requires and gives the external reviewer a clear record to review.